CannAssist International Corp.’s (CNSC) Propriet
Post# of 77
(Total Views: 290)
Posted On: 01/06/2021 3:38:40 PM
CannAssist International Corp.’s (CNSC) Proprietary CiBiDinol Technology Promises to Outperform Conventional CBD Oil for Superior Pain-Relief
- Market for CBD-based pain relief products is growing rapidly, projected to reach $20 billion by 2024
- CNSC is a biotech company that produces fast-acting CBD products under the Xceptol brand
- Xceptol products are formulated with exclusive technology that increases absorbability, bioavailability, shelf life
- Third-party testing on Xceptol suggests 400% increase in skin penetration, 300% increase in gut absorption when compared to regular oil-based CBD
CannAssist International (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand – a line of cannabidiol (“CBD”) products that promises increased absorption, bioavailability and longer shelf life.
An aging population coupled with increased chronic stress among younger people contributes to the rapidly growing market for CBD-based pain relief products—a market projected to reach $20 billion by 2024 (https://nnw.fm/MGY77). Cannabidiol – a therapeutic component of the cannabis plant—has been studied extensively and has been shown to reduce inflammation while providing pain relief (https://nnw.fm/VMxsU). As concerns about the dangerous toxicity of mainstream pharmaceuticals like Acetaminophen continue to rise (https://nnw.fm/uVGon), more people than ever before are turning to CBD for a gentler way to relieve pain and reduce inflammation.
CiBiDinol is created using a proprietary process specifically developed to overcome numerous critical issues with oil-soluble CBD molecules. These include treatment administration, absorbability, bioavailability, and the short shelf-life of oil-based CBD products. Through the company’s proprietary process, CBD molecules are combined with penetration-enhancing cyclodextrin to cover the surface of the oil-soluble CBD molecule in a water-soluble carrier rendering it water dispersible. The resulting product has been shown to enhance absorption through the skin and gut with the overall goal of administering CBD in a way that is better aligned with the body’s natural bioactivity.
Due to increased absorption, CNSC believes that its technology also offers a more potent product with greater efficacy per dose. Testing conducted via third-party services has confirmed these claims, suggesting that products created with CiBiDinol demonstrate a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD (https://nnw.fm/BDIXY). Given the outcome of these tests, the company believes that the amount of CBD needed to achieve the targeted therapeutic effects can be reduced significantly, resulting in reduced costs for both manufacturers and consumers.
Since its launch in September 2020, the Xceptol line of products includes five National Drug Codes topical pain creams utilizing ingredients registered with the FDA, capsules and tinctures. Xceptol’s CiBiDinol products are sold online through the Range Me product marketplace along with geographical distributors across established sales channels in North America. Efforts to establish international distribution channels are underway in Central America, South America, South Africa, the EU, the UK and the Philippines. With the goal of targeting the pain-relief market, Xceptol products will be marketed through multiple social media campaigns using celebrities and former athletes associated with Freedman Sports Promotional Relations.
Headquartered in San Diego, California, CannAssist was established in May 2017 with the goal of providing superior CBD products for a growing diverse market.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Market for CBD-based pain relief products is growing rapidly, projected to reach $20 billion by 2024
- CNSC is a biotech company that produces fast-acting CBD products under the Xceptol brand
- Xceptol products are formulated with exclusive technology that increases absorbability, bioavailability, shelf life
- Third-party testing on Xceptol suggests 400% increase in skin penetration, 300% increase in gut absorption when compared to regular oil-based CBD
CannAssist International (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand – a line of cannabidiol (“CBD”) products that promises increased absorption, bioavailability and longer shelf life.
An aging population coupled with increased chronic stress among younger people contributes to the rapidly growing market for CBD-based pain relief products—a market projected to reach $20 billion by 2024 (https://nnw.fm/MGY77). Cannabidiol – a therapeutic component of the cannabis plant—has been studied extensively and has been shown to reduce inflammation while providing pain relief (https://nnw.fm/VMxsU). As concerns about the dangerous toxicity of mainstream pharmaceuticals like Acetaminophen continue to rise (https://nnw.fm/uVGon), more people than ever before are turning to CBD for a gentler way to relieve pain and reduce inflammation.
CiBiDinol is created using a proprietary process specifically developed to overcome numerous critical issues with oil-soluble CBD molecules. These include treatment administration, absorbability, bioavailability, and the short shelf-life of oil-based CBD products. Through the company’s proprietary process, CBD molecules are combined with penetration-enhancing cyclodextrin to cover the surface of the oil-soluble CBD molecule in a water-soluble carrier rendering it water dispersible. The resulting product has been shown to enhance absorption through the skin and gut with the overall goal of administering CBD in a way that is better aligned with the body’s natural bioactivity.
Due to increased absorption, CNSC believes that its technology also offers a more potent product with greater efficacy per dose. Testing conducted via third-party services has confirmed these claims, suggesting that products created with CiBiDinol demonstrate a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD (https://nnw.fm/BDIXY). Given the outcome of these tests, the company believes that the amount of CBD needed to achieve the targeted therapeutic effects can be reduced significantly, resulting in reduced costs for both manufacturers and consumers.
Since its launch in September 2020, the Xceptol line of products includes five National Drug Codes topical pain creams utilizing ingredients registered with the FDA, capsules and tinctures. Xceptol’s CiBiDinol products are sold online through the Range Me product marketplace along with geographical distributors across established sales channels in North America. Efforts to establish international distribution channels are underway in Central America, South America, South Africa, the EU, the UK and the Philippines. With the goal of targeting the pain-relief market, Xceptol products will be marketed through multiple social media campaigns using celebrities and former athletes associated with Freedman Sports Promotional Relations.
Headquartered in San Diego, California, CannAssist was established in May 2017 with the goal of providing superior CBD products for a growing diverse market.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)